Skip to content
Reipet – Lifestyle
Author:
NewAmsterdam Pharma N.V.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
September 29, 2026
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
September 21, 2026
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 3, 2026
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
September 2, 2026
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 6, 2026
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
August 5, 2026
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
July 29, 2026
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
July 24, 2026
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 2, 2026
1
2
Next Page
→